Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis

I Cromwell, K van der Hoek, SCM Taylor, B Melosky… - Lung Cancer, 2012 - Elsevier
Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …
被引用次数：34 相关文章

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis

I Cromwell, K van der Hoek… - Lung cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

I Cromwell, K van der Hoek, SCM Taylor, B Melosky… - Lung Cancer, 2012 - infona.pl
Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

[引用][C] Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

I Cromwell, K van der Hoek, SCM Taylor, B Melosky… - Lung Cancer, 2012 - cir.nii.ac.jp
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung
cancer: A real-world cost-effectiveness analysis | CiNii Research CiNii 国立情報学研究所 学術 …

[引用][C] Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

I CROMWELL, KV DER HOEK… - Lung …, 2012 - pascal-francis.inist.fr
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung
cancer: A real-world cost-effectiveness analysis CNRS Inist Pascal-Francis CNRS Pascal …

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

I Cromwell, K van der Hoek, SCM Taylor… - Lung …, 2012 - lungcancerjournal.info
Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

I Cromwell, K van der Hoek, MT SC… - Lung Cancer …, 2012 - europepmc.org
Methods In a population of patients who have been treated with drugs for advanced NSCLC,
overall survival (OS), progression-to-death survival (PTD) and probability of survival one …

[引用][C] Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

I CROMWELL, KV DER HOEK, SC MALFAIRTAYLOR… - Lung cancer, 2012 - Elsevier